Gene therapy strategies: Can we eradicate HIV?

Current HIV/AIDS Reports

Volumn 8, Issue 2, 2011, Pages 78-84

  Van Lunzen, Jan ^a,b   Fehse, Boris ^a   Hauber, Joachim ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

Genotoxicity; Hematopoietic stem cells; HIV eradication; HIV gene therapy; Intracellular immunization

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; HISTONE DEACETYLASE INHIBITOR; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; ZINC FINGER PROTEIN;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; ERADICATION THERAPY; GENE TRANSFER; GENETIC SELECTION; GENETIC TRANSDUCTION; GENOTOXICITY; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RIBOZYME THERAPY; STEM CELL TRANSPLANTATION; TRANSGENE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HUMANS;

EID: 79957480484     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-011-0073-9     Document Type: Article

References (54)

1. S Palmer F Maldarelli A Wiegand, et al. 2008 Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy Proc Natl Acad Sci USA 105 3879 84 18332425 10.1073/pnas.0800050105 1:CAS:528: DC%2BD1cXjslSiur0%3D (Pubitemid 351723493)
2. JM Brenchley DA Price TW Schacker, et al. 2006 Microbial translocation is a cause of systemic immune activation in chronic HIV infection Nat Med 12 1365 714 17115046 10.1038/nm1511 1:CAS:528:DC%2BD28Xht1OntbnK (Pubitemid 44924494)
3. van Lunzen J, Hoffmann C. Virological rebound and its consequences during treatment interruption. Curr Opin HIV & AIDS. 2007;(2):1-5 5. (Pubitemid 46941135)
4. D Finzi M Hermankova T Pierson, et al. 1997 Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 278 1295 300 9360927 10.1126/science.278.5341.1295 1:CAS:528:DyaK2sXntlOmsro%3D (Pubitemid 27495742)
5. D Finzi J Blankson JD Siliciano, et al. 1999 Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy Nat Med 5 512 7 10229227 10.1038/8394 1:CAS:528:DyaK1MXivVKksro%3D (Pubitemid 29220209)
6. J van Lunzen 2007 How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV infection Eur J Med Res 12 1 6
7. JM Murray S Emery AD Kelleher, et al. 2007 Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase AIDS 21 2315 21 18090280 10.1097/QAD.0b013e3282f12377 1:CAS:528:DC%2BD2sXhsVKjsr3L (Pubitemid 350287458)
8. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 16:460-5.
9. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 7.
10. Delaugerre C, Charreau I, Braun J, et al. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. Aids. 24:2391-5.
11. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 50:912-9.
12. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. Aids.
13. R Walker RM Blaese CS Carter L Chang H Klein HC Lane, et al. 1993 A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins Hum Gene Ther 4 5 659 80 8280803 10.1089/hum.1993.4.5-659 1:STN:280:DyaK2c7gsl2ltg%3D%3D
14. J van Lunzen T Glaunsinger I Stahmer V von Baehr C Baum A Schilz, et al. 2007 Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug resistant viruses Mol Ther 15 5 1024 33 17356541 (Pubitemid 46621662)
15. RT Mitsuyasu TC Merigan A Carr JA Zack MA Winters C Workman, et al. 2009 Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells Nat Med 15 3 285 92 19219022 10.1038/nm.1932 1:CAS:528:DC%2BD1MXhvFKjt74%3D
16. •• von Laer D, Baum C, Schambach A, Kuehlcke K, Zahn R, Newrzela S, et al. Gene therapeutic approaches for immune modulation in AIDS. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. 2007(6):121-140. This is a comprehensive review on the current concepts of gene therapy in HIV infection. Basic research and concepts are thoroughly discussed and translated into clinical trials.
17. L Colin C Van Lint 2009 Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies Retrovirology 6 111 19961595 10.1186/1742-4690-6-111
18. JJ Rossi CH June DB Kohn 2007 Genetic therapies against HIV Nat Biotechnol 25 1444 54 18066041 10.1038/nbt1367 1:CAS:528:DC%2BD2sXhsVSjurrF (Pubitemid 350233141)
19. T Dull R Zufferey M Kelly RJ Mandel M Nguyen D Trono, et al. 1998 A third-generation lentivirus vector with a conditional packaging system J Virol 72 8463 71 9765382 1:CAS:528:DyaK1cXmslaisbc%3D (Pubitemid 28471781)
20. J Münch E Rücker L Ständker K Adermann C Goffinet M Schindler, et al. 2007 Semen-derived amyloid fibrils drastically enhance HIV infection Cell 131 1059 71 18083097 10.1016/j.cell.2007.10.014 (Pubitemid 350235017)
21. D von Laer S Hasselmann K Hasselmann 2006 Impact of gene-modified T cells on HIV infection dynamics J Theor Biol 238 60 77 10.1016/j.jtbi.2005.05.005 (Pubitemid 41737797)
22. G Hütter D Nowak M Mossner S Ganepola A Müig K Allers, et al. 2009 Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation N Engl J Med 360 692 8 19213682 10.1056/NEJMoa0802905 This study demonstrated for the first time the eradication of HIV-1 in a patient successfully transplanted with allogeneic CCR5-negative hematopoietic stem cells
23. Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell transplantation. Blood. 2010 Dec 8. [Epub ahead of print].
24. AD Friedman SJ Triezenberg SL McKnight 1988 Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus Nature 335 6189 452 4 2843776 10.1038/335452a0 1:CAS:528:DyaL1MXlt1SrtQ%3D%3D
25. D Baltimore 1988 Gene therapy. Intracellular immunization Nature 335 6189 395 6 3166513 10.1038/335395a0 1:STN:280:DyaL1czjsVOitQ%3D%3D
26. M McCarthy 1993 Gene therapy for HIV infection Lancet 342 8874 799 8103884 1:STN:280:DyaK3szot1agug%3D%3D
27. RA Morgan ME Dudley JR Wunderlich MS Hughes JC Yang RM Sherry, et al. 2006 Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 5796 126 9 16946036 10.1126/science.1129003 1:CAS:528:DC%2BD28XhtVCiurrK (Pubitemid 44547756)
28. A Aiuti F Cattaneo S Galimberti U Benninghoff B Cassani L Callegaro, et al. 2009 Gene therapy for immunodeficiency due to adenosine deaminase deficiency N Engl J Med 360 5 447 58 19179314 10.1056/NEJMoa0805817 1:CAS:528: DC%2BD1MXhtF2rtb0%3D This work has confirmed the potential of successful long-term correction of inborn severe combined immunodeficiency
29. GD Trobridge RA Wu BC Beard SY Chiu NM Muñoz D von Laer, et al. 2009 Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection PLoS ONE 4 11 e7693 19888329 10.1371/journal.pone. 0007693 This is a clear demonstration that in vivo selection of hematopoietic stem cells "immunized" against HIV is possible
30. RS Mitchell BF Beitzel AR Schroder P Shinn H Chen CC Berry, et al. 2004 Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences PLoS Biol 2 8 E234 15314653 10.1371/journal.pbio.0020234 (Pubitemid 39245268)
31. FA Santoni O Hartley J Luban 2010 Deciphering the code for retroviral integration target site selection PLoS Comput Biol 6 11 e1001008 21124862 10.1371/journal.pcbi.1001008
32. C Baum J Düllmann Z Li B Fehse J Meyer DA Williams, et al. 2003 Side effects of retroviral gene transfer into hematopoietic stem cells Blood 101 2099 114 12511419 10.1182/blood-2002-07-2314 1:CAS:528:DC%2BD3sXit1egs74%3D (Pubitemid 36302043)
33. S Stein MG Ott S Schultze-Strasser A Jauch B Burwinkel A Kinner, et al. 2010 Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease Nat Med 16 2 198 204 20098431 10.1038/nm.2088 1:CAS:528:DC%2BC3cXpslGjsA%3D%3D This is a detailed analysis of side effects in a gene therapy trial for chronic granulomatous disease
34. E Montini D Cesana M Schmidt F Sanvito M Ponzoni C Bartholomae, et al. 2006 Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration Nat Biotechnol 24 6 687 96 16732270 10.1038/nbt1216 1:CAS:528:DC%2BD28XlsVCjsrs%3D (Pubitemid 43882120)
35. U Modlich J Bohne M Schmidt C von Kalle S Knöss A Schambach, et al. 2006 Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity Blood 108 8 2545 53 16825499 10.1182/blood-2005-08- 024976 1:CAS:528:DC%2BD28XhtFWgt7fE
36. D Zychlinski A Schambach U Modlich T Maetzig J Meyer E Grassman, et al. 2008 Physiological promoters reduce the genotoxic risk of integrating gene vectors Mol Ther 16 4 718 25 18334985 10.1038/mt.2008.5 1:CAS:528: DC%2BD1cXjslCntrk%3D (Pubitemid 351426173)
37. K Cornils C Lange A Schambach MH Brugman R Nowak M Lioznov, et al. 2009 Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance Mol Ther 17 131 43 19002163 10.1038/mt.2008.238 1:CAS:528:DC%2BD1MXmtlWi
38. E Montini D Cesana M Schmidt F Sanvito CC Bartholomae M Ranzani, et al. 2009 The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy J Clin Invest 119 4 964 75 10.1172/JCI37630 19307726 10.1172/JCI37630 1:CAS:528:DC%2BD1MXktlSnt7c%3D
39. M Cavazzana-Calvo E Payen O Negre G Wang K Hehir F Fusil, et al. 2010 Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia Nature 467 7313 318 22 20844535 10.1038/nature09328 1:CAS:528:DC%2BC3cXhtFOhtL7P This study has shown that insertional mutagenesis remains a risk factor in clinical gene therapy even with safety-optimized lentiviral vectors
40. OS Kustikova B Schiedlmeier MH Brugman M Stahlhut S Bartels Z Li, et al. 2009 Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis Mol Ther 17 9 1537 47 19532134 10.1038/mt.2009.134 1:CAS:528:DC%2BD1MXntlGnsb0%3D
41. S Newrzela K Cornils Z Li C Baum MH Brugman M Hartmann, et al. 2008 Resistance of mature T cells to oncogene transformation Blood 112 2278 86 18566328 10.1182/blood-2007-12-128751 1:CAS:528:DC%2BD1cXhtFCrurnO In direct contrast with hematopoietic stem cells, polyclonal T cells were shown to be strongly resistant toward malignant transformation
42. J Bohne T Cathomen 2008 Genotoxicity in gene therapy: an account of vector integration and designer nucleases Curr Opin Mol Ther 10 3 214 23 18535928 1:CAS:528:DC%2BD1cXoslOkurY%3D Nice overview on strategies to overcome genotoxicity of integrating gene transfer vectors (Pubitemid 351799272)
43. L Mátés MK Chuah E Belay B Jerchow N Manoj A Acosta-Sanchez, et al. 2009 Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates Nat Genet 41 6 753 61 19412179 10.1038/ng.343
44. TI Cornu T Cathomen 2007 Targeted genome modifications using integrase-deficient lentiviral vectors Mol Ther 15 12 2107 13 17998901 10.1038/sj.mt.6300345 1:CAS:528:DC%2BD2sXhtlalsr3N (Pubitemid 350148926)
45. A Lombardo P Genovese CM Beausejour S Colleoni YL Lee KA Kim, et al. 2007 Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery Nat Biotechnol 25 11 1298 306 17965707 10.1038/nbt1353 1:CAS:528:DC%2BD2sXht1Oru7zO Epub 2007 Oct 28. This work proves the possibility to edit gene loci (as CCR5) in hematopoietic stem cells using non-integrating lentiviral vectors (Pubitemid 350076515)
46. OS Kustikova A Wahlers K Kühlcke B Stähle AR Zander C Baum, et al. 2003 Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population Blood 102 3934 7 12881303 10.1182/blood-2003-05-1424 1:CAS:528: DC%2BD3sXpsFamu78%3D (Pubitemid 37486973)
47. B Fehse I Roeder 2008 Insertional mutagenesis and clonal dominance-biological and statistical considerations Gene Ther 15 143 53 17972922 10.1038/sj.gt.3303052 1:CAS:528:DC%2BD1cXhtlKjsQ%3D%3D
48. D von Laer S Hasselmann K Hasselmann 2006 Gene therapy for HIV infection: what does it need to make it work? J Gene Med 8 6 658 67 10.1002/jgm.908
49. N Holt J Wang K Kim G Friedman X Wang V Taupin, et al. 2010 Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo Nat Biotechnol 28 839 47 20601939 10.1038/nbt.1663 1:CAS:528:DC%2BC3cXotlWktL4%3D This study demonstrates antiviral effects in humanized mice, which were engrafted with human hematopoietic progenitor cells. Prior to transplantation, the human cells were treated with CCR5 gene-inactivating zinc finger nuclease
50. EE Perez J Wang JC Miller Y Jouvenot KA Kim O Liu, et al. 2008 Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases Nat Biotechnol 26 808 16 18587387 10.1038/nbt1410 1:CAS:528:DC%2BD1cXot1ent7k%3D A study demonstrating long-lived CCR5 inhibition using zinc finger nuclease (Pubitemid 351961450)
51. A Lombardo P Genovese CM Beausejour S Colleoni YL Lee KA Kim, et al. 2007 Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery Nat Biotechnol 25 1298 306 17965707 10.1038/nbt1353 1:CAS:528:DC%2BD2sXht1Oru7zO (Pubitemid 350076515)
52. I Sarkar I Hauber J Hauber F Buchholz 2007 HIV-1 proviral DNA excision using an evolved recombinase Science 316 1912 5 17600219 10.1126/science.1141453 1:CAS:528:DC%2BD2sXmvV2mu7s%3D This study reports the quantitative excision of HIV-1 provirus from human chromosomal DNA by expression of an engineered LTR-specific recombinase (Pubitemid 47025793)
53. M Lewandoski 2001 Conditional control of gene expression in the mouse Nat Rev Genet 2 743 55 11584291 10.1038/35093537 1:CAS:528:DC%2BD38Xmt1Wgtbk%3D (Pubitemid 33685572)
54. CS Branda SM Dymecki 2004 Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice Dev Cell 6 7 28 14723844 10.1016/S1534-5807(03)00399-X 1:CAS:528:DC%2BD2cXntlalug%3D%3D (Pubitemid 38089202)